October 2014, Issue 1

October 2014

Issue 1

This issue features essential information for clinical practice, education, and research.

Table of Contents

October 2014

A New ASH Publication Dawns

Wednesday, October 1st, 2014
Welcome to the first edition of ASH Clinical News magazine! This new, monthly publication from the American Society of Hematology arose in response to the...

October 2014

Wednesday, October 1st, 2014
ASH Brings Sickle Cell Disease Awareness to Capitol Hill The National Heart, Lung, and Blood In-stitute’s (NHLBI) recently released expert panel report on the management...

October 2014

“Still” Photography (Part 1 of 2) by Jason Gotlib, MD, MS

Wednesday, October 1st, 2014
PASHions will highlight what ASH Clinical News readers do creatively outside of practice. If you have a creative skill in the arts you’d like...

Pulling Back the Curtain: Linda J. Burns, MD

Wednesday, October 1st, 2014
What was your first job? I grew up on a working farm in northern Missouri, so really, my first job was doing chores. My...

The Road to the New Sickle Cell Disease Guidelines: Interview with Co-Chair George R....

Wednesday, October 1st, 2014
On September 9, 2014, the National Heart, Lung, and Blood Institute (NHLBI) released an evidence-based expert panel report on the management of sickle cell...

Has ABIM Gone Too Far?

Wednesday, October 1st, 2014
Recently, the American Board of Internal Medicine (ABIM) announced plans to implement new Maintenance of Certification (MOC) requirements, including requiring physicians to complete some...

October 2014

Clinical Trials 101

Wednesday, October 1st, 2014
A clinical trial is a research study involving human volunteers to evaluate new ways to prevent, diagnose, or treat diseases. Clinical trials help determine...

The “KIST” Principle of Teaching

Wednesday, October 1st, 2014
I have been practicing hematology for a long time. I have attended many ASH meetings, including innumerable education, scientific, and poster sessions. After every...

October 2014

DS-ALL: An Ever-Changing Genetic Mutation Landscape

Wednesday, October 1st, 2014
Children with Down syndrome are at an increased risk for developing leukemia – as much as 50 times more likely than other children. In...

A Possible Cheaper Test for Sickle Cell, Leukemia Drug May be Applicable to Other...

Wednesday, October 1st, 2014
A Cheaper, Faster Test for Sickle Cell? Twelve minutes and 50 cents could be all it takes to diagnose sickle cell disease (SCD), if the...
WIB_icon

Once-Weekly Bortezomib Produced Durable Responses, Survival in Relapsed AL Amyloidosis

Wednesday, October 1st, 2014
Results from a phase I/II study of single-agent bortezomib suggest that a once-weekly dosing regimen produced similar efficacy results to a twice-weekly regimen —...
WIB_icon

The Earlier the Better Early Response to Imatinib Predicted Outcomes in Children with CML

Wednesday, October 1st, 2014
While imatinib has been proven effective for the majority of pediatric patients with chronic myeloid leukemia (CML), 13 to 25 percent of children still...
WIB_icon

Moderate-Dose Cyclophosphamide for Severe Aplastic Anemia:Potential Toxicity Outweighs Potential Benefit

Wednesday, October 1st, 2014
While cyclophosphamide at high or more moderate doses can be active in severe aplastic anemia, a new study published in Blood reveals that a...
WIB_icon

New Target Holds Potential for Treatment of Common Anemia

Wednesday, October 1st, 2014
Lexaptepid, an anti-hepcidin therapy, may be the first viable treatment option for patients with anemia of inflammation, according to the results of an experimental...

Good, But Not Optimal – HSCT Match Possible for Most Patients

Wednesday, October 1st, 2014
For patients with certain blood cancers or other diseases, hematopoietic stem cell transplants (HSCT) are potentially lifesaving therapies. While the majority of patients are...

Ruxolitinib Shows Promise in Polycythemia Vera

Wednesday, October 1st, 2014
Ruxolitinib, a JAK1/2 inhibitor approved by the FDA for the treatment of myelofibrosis, also has activity in another myeloproliferative neoplasm, polycythemia vera, according to...

October 2014

Mechanisms of Ibrutinib Resistance Varied in ABC DLBCL

Wednesday, October 1st, 2014
Lymphoma cells may develop resistance to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib using a variety of potentially druggable pathways, opening the door to...

Early Data Show EZH2 Inhibitor Active in Non-Hodgkin Lymphoma

Wednesday, October 1st, 2014
The EZH2 inhibitor EPZ-6438 appears to be a well-tolerated drug and is showing early evidence of anti-lymphoma activity in patients with non-Hodgkin lymphoma of...

Potent Small-Molecule BCL6 Inhibitor Active against ABC-, GCB-DLBCL Cells

Wednesday, October 1st, 2014
Researchers have identified a novel, potent, and specific BCL6 inhibitor that effectively inhibited tumor growth in vitro and in vivo in activated B-cell (ABC)...

ASH Meeting on Lymphoma Biology: Creating a Roadmap for Future Research

Wednesday, October 1st, 2014
More than 350 lymphoma experts from around the world convened at the American Society of Hematology’s first Meeting on Lymphoma Biology to share cutting-edge...

2014 ASH Annual Meeting Program Preview: A Discussion with Program Co-Chairs

Wednesday, October 1st, 2014
Now that the “ASH Dash” to submit abstracts is finished, we can look forward to taking advantage of everything this year’s annual meeting in...

SHARE